Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ2PC5
|
|||
| Drug Name |
TAK-925
|
|||
| Synonyms |
Danavorexton; TAK-925; 2114324-48-8; Danavorexton [INN]; 1QMD83K4YN; (2R,3S)-Methyl 3-(methylsulfonamido)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate; 1-Piperidinecarboxylic acid, 3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)-, methyl ester, (2R,3S)-; Methyl (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate; methyl (2R,3S)-3-[(methanesulfonyl)amino]-2-({[(1s,4S)-4-phenylcyclohexyl]oxy}methyl)piperidine-1-carboxylate; A6F; UNII-1QMD83K4YN; TAK925; CHEMBL4650341; SCHEMBL19219900; GTPL11448; US10287305, Example 5; BDBM386067; BDBM386216; DTXSID401336757; GLXC-25309; EX-A6332; Example 5 [US10287305]; US10287305, Example 191; AKOS040757301; MS-27472; HY-133898; CS-0135024; EN300-2010728; methyl (2R,3S)-3- ((methylsulfonyl)amino)-2-(((cis-4- phenylcyclohexyl)oxy)methyl)- piperidine-1-carboxylate; methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate; methyl (2R,3S)-3-methanesulfonamido-2-({[(1s,4s)-4-phenylcyclohexyl]oxy}methyl)piperidine-1-carboxylate; methyl-d3 (2R,3S)-3- ((methylsulfonyl)amino)-2-(((cis-4- phenylcyclohexyl)oxy)methyl)- piperidine-1-carboxylate
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Narcolepsy [ICD-11: 7A20; ICD-10: G47.4] | Phase 1 | [1] | |
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H32N2O5S
|
|||
| Canonical SMILES |
COC(=O)N1CCCC(C1COC2CCC(CC2)C3=CC=CC=C3)NS(=O)(=O)C
|
|||
| InChI |
InChI=1S/C21H32N2O5S/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22H,6,9-15H2,1-2H3/t17?,18?,19-,20-/m0/s1
|
|||
| InChIKey |
UXZAJSZFFARTEI-GUMHCPJTSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Orexin receptor type 2 (HCRTR2) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03748979) A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy. U.S.National Institutes of Health. | |||
| REF 2 | Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.